NCI selects Advaita Bio for NCI site-wide Next-gen Bioinformatics solution provider

Advaita Bio’s iPathwayGuide was chosen after a lengthy evaluation to be a side-wide solutions provider for the analysis of mRNA and protein expression data for all researchers attached to the National Cancer Institute (NCI). Its ease of use, advance analytic capabilities, and price point were all factors in its selection.

​Andrew Olson, Vice President of Business Development remarked, “It is a great honor to be recognized by NCI, one of the Nation’s premier cancer research organizations, as having a world-class solution for the analysis of these high-throughput data.” He continued, “We look forward to working with NCI to expand iPathwayGuide’s adoption and usefulness in the research work at NCI.”

iPathwayGuide is a web-based application designed to take the results from phenotype comparison experiments (e.g. disease vs. control) and analyze the changes in expression levels of genes and or proteins. iPathwayGuide analyzes these data in the context of predicted micro RNA (miRNA) activity, gene ontology terms, pathways, and diseases. Its unique patented capabilities include the ability to assess how perturbed a pathway is by assessing the relationships that exists between each and every gene. In this way, iPathwayGuide can eliminate the many false positives that are indicative of other similar pathway analysis applications.

Advaita makes bioinformatics applications for the analysis and interpretation of expression data and variant data. They have over 8,500 users of its applications in over 100 countries throughout the world. Its headquarters are located just outside of Ann Arbor, Michigan. More information about the company and its products can be found at www.AdvaitaBio.com.